Minerva Neurosciences Q2 2026 Results and Roluperidone Phase 3 Update

Minerva Neurosciences reported financial results for the second quarter ended June 30, 2026, and provided a business update on its lead candidate, roluperidone (MIN-101C19). The company is currently conducting the C19 Study, a global confirmatory Phase 3 clinical trial targeting negative symptoms of schizophrenia. The trial is designed in two parts: Phase A to evaluate efficacy at 12 weeks versus placebo, and Phase B to evaluate longer-term relapse over 52 weeks. Topline efficacy data for Phase A is expected in the second half of 2027, with Phase B data anticipated in the second half of 2028. Financially, Minerva reported a GAAP net income of $17.5 million for Q2 2026, primarily driven by a $27.6 million non-cash gain from the change in fair value of warrant liabilities. On a non-GAAP basis, the adjusted net loss was $7.8 million. Research and development expenses rose to $7.2 million for the quarter, up from $1.3 million in the prior year, due to C19 trial costs. As of June 30, 2026, the company held $75.4 million in cash, cash equivalents, and marketable securities.